In October 2012, Compendia Bioscience Inc was acquired by Life Technologies Corporation - a biotechnology company involved in the fields of scientific research, genetic analysis and applied sciences - itself an SBIR-involved firm having been formed as an amalgamation of Invitrogen and Applied Biosystems in 2008 subsequently in Feb 2014, itself acquired by Thermo Fisher Scientific Corporation. Compendia Bioscience, Inc. gathers high-throughput biology data, making that data interpretable and applicable in target identification/ validation, drug development, and clinical research to ultimately improve the lives of patients. Compendia Bioscienceâs flagship product, Oncomine, integrates and unifies this data so that target expression across thousands of human tumors, hundreds of cancer types and subtypes, and millions of dollars of experiments can be assessed online in seconds. Oncomine enables users to discover and prioritize potential cancer targets and biomarkers, improving efficiency, strengthening product pipelines and increasing the likelihood of succes
